No Data
Nxera Pharma's Schizophrenia Treatment Enters Phase 3 Trials
Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations
Kyowa Kirin, Mitsui & Co., Sumitomo Corp., Yamato HD (on the 1st).
※ The above Calendar is merely a schedule and may be subject to change due to the company's circumstances.--------------------------------------- May 1 (Thursday) <2148> ITM <2551> Marusan Ai <2579> Coca BJH <2768> Sojitz <299A> dely <3064> MonotaRO <4151> Kyowa Kirin <4206> Ai
Kinden, Yamazaki Pan ETC (additional) Rating
Downgrade - Bearish Code Stock Name Securities Company Previous After--------------------------------------------------------------<6523> PHCHD Morgan Stanley "Equal Weight" "Under Weight" <8591> ORIX Morgan Stanley "Over Weight" "Equal Weight" Target Price Change Code Stock Name Securities Company Previous After------------------------------------
Rating Information (Target Price Change - Part 1) = Kindan, Nexela, etc.
Nomura Securities (three-tier system: Buy > Neutral > Reduce) Kinden <1944.T> - "Buy" → "Buy", 4030 yen → 4260 yen Fujielectric <6504.T> - "Buy" → "Buy", 10200 yen → 9100 yen TDK <6762.T> - "Buy" → "Buy", 2450 yen → 2180 yen Keyence <6861.T> - "Buy" → "Buy", 79000 yen → 75000 yen Murata Manufacturing <6981.T> - "Buy" → "Buy"
Aftermarket [Stocks that moved and stocks that were traded]
*Pasona <2168> 2155 +140 The cumulative operating profit and loss for the third quarter is a deficit of 1.28 billion yen, but the feeling of easing is dominant. *Needs Well <3992> 417 +61 A shareholder benefit system has been introduced. *Ecomott <3987> 444 +80 The operating profit for the first half is 0.044 billion yen. It turned from a deficit of 0.036 billion yen in the first quarter to a surplus. A share buyback with a limit of 2.85% of the issued stocks was also announced. *Flyer <323A> 703 +100 Evaluating the profit trends. The operating profit and loss is 24.